• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vera Therapeutics Inc.

    12/3/25 4:31:59 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001819688
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    VERA THERAPEUTICS INC
    SEC File Number
    001-40407
    Address of Issuer
    2000 Sierra Point Parkway, Suite 1200
    Brisbane
    CALIFORNIA
    94005
    Phone
    6507700077
    Name of Person for Whose Account the Securities are To Be Sold
    WILLIAM TURNER
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10000372500.006392806612/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/03/2025Exercise of Stock OptionsIssuerCheckbox not checked1000012/03/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/03/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    02/20/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ William Turner

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    10/16/2025$48.00Buy
    BofA Securities
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    More analyst ratings

    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Vera Therapeutics with a new price target

    BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00

    10/16/25 8:29:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Vera Therapeutics from Outperform to Peer Perform

    8/4/25 8:19:45 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

    5/5/25 9:37:24 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Regulatory Officer Turner William D. exercised 10,000 shares at a strike of $15.53 and sold $400,000 worth of shares (10,000 units at $40.00) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/4/25 4:05:47 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Meyers James R

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    11/26/25 4:37:03 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Meyers James R

    3 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    11/26/25 4:35:02 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    SEC Filings

    View All

    SEC Form 144 filed by Vera Therapeutics Inc.

    144 - Vera Therapeutics, Inc. (0001831828) (Subject)

    12/3/25 4:31:59 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    11/26/25 4:30:26 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vera Therapeutics Inc.

    SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/25 12:19:23 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on De

    12/5/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics to Participate at Upcoming Investor Conferences

    BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: 8th Annual Evercore Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/evercore52/vera/2362844Date: Tuesday, December 2, 2025 Time: 8:45am ET Location: Coral Gables, FL Citi 2025 Global Healthcare ConferenceFormat: Fireside Chat and 1x1

    11/24/25 7:25:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

    BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

    11/18/24 8:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

    BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

    7/1/24 8:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:05:17 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vera Therapeutics Inc.

    SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 1:22:39 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Financials

    Live finance-specific insights

    View All

    Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

    Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application

    6/2/25 6:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

    BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

    1/13/25 7:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

    New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

    6/17/23 10:10:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    6/25/25 8:07:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/1/24 5:58:54 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care